Patient Guide: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 40 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06365853
Status: 🟢 Enrolling Now
Condition: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Phase: PHASE2

Where You Can Participate

This study is available at 40 locations across the country.

Top locations include:
  • • Los Angeles, California
  • • Louisville, Kentucky
  • • Silver Spring, Maryland
  • • And 37 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression - Join Clinical Trial NCTNCT06365853

How to Join This Clinical Trial - NCTNCT06365853

Learn how to participate in this PHASE2 trial studying an investigational therapy for Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06365853 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 40 locations. Find a study site near you:

Clinical Research Site

Los Angeles, California 90095 - United States

Status: RECRUITING

Clinical Research Site

Louisville, Kentucky 40207 - United States

Status: COMPLETED

Clinical Research Site

Silver Spring, Maryland 20910 - United States

Status: RECRUITING

Clinical Research Site

St Louis, Missouri 63141 - United States

Status: RECRUITING

Clinical Research Site

Reno, Nevada 89511 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Teaneck, New Jersey 07666 - United States

Status: RECRUITING

Clinical Research Site

Albany, New York 12206-5013 - United States

Status: COMPLETED

Clinical Research Site

Albany, New York 12208 - United States

Status: COMPLETED

Clinical Research Site

Durham, North Carolina 27710 - United States

Status: RECRUITING

Clinical Research Site

Akron, Ohio 44304-1407 - United States

Status: RECRUITING

And 30 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships